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ABSTRACT
Context: Patients with end-stage renal disease can easily acquire a hepatitis C virus 
(HCV) infection via several ways. An HCV infection is diﬃcult to treat after renal trans-
plantation due to the conﬂicting actions of immunosuppressant therapy to maintain 
the function of the transplanted kidney and viricidal interferon (IFN) or ribavirin 
(RBV) treatment. Antiviral therapy requires great caution to avoid the complex and po-
tentially fatal pharmacological eﬀects. In this review, we examined clinical challenges 
and potential solutions for this speciﬁc scenario. 
Evidence Acquisitions: We searched Pubmed (NLM), LISTA (EBSCO), Web of Science (TS). 
The management of patients on waiting list, the indications and regimens about treat-
ment were studied.
Results: More than forty papers about this topic were found, including seven small 
clinical trials. International consensus has been reached to test patients awaiting re-
nal transplantation. HCV detection after renal transplantation warrants careful con-
sideration of when to initiate antiviral therapy. Treatment will begin immediately if 
deteriorating liver function increases the risk for loss of renal function. The choice of 
regimen depends on the patient’s renal function and is individualized under close 
observation. The immunosuppressive regimen will be adjusted accordingly before 
antiviral therapy is initiated. 
Conclusions: The eﬀects of modiﬁed antiviral therapy on these patients varies because 
of individual characteristics and disease state, and also because of the diﬃculty asso-
ciated with conducting a large clinical trial to obtain statistically sound conclusions. 
The management before transplantation is important and when antiviral therapy 
needs to start, careful consideration of risks and beneﬁts is needed before initiating 
this type of treatment.
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1. Context
Patients with   end-stage renal disease (ESRD) are re-
quired to undergo planned hemodialysis before renal 
transplantation is considered (1). Dialysis is also neces-
sary to improve a patient’s quality of life while awaiting 
renal transplantation. Protracted exposure to externali-
ties during hemodialysis increases the risk of infection 
and blood-borne disease, especially hepatitis C virus 
(HCV). The hypoimmunity characterizing these patients 
is an important predisposing factor for HCV infection (2). 
If these patients become infected with HCV at the dialysis 
stage, clinicians face a big challenge managing the liver 
disease due to the conﬂicting pharmacological eﬀects 
resulting from concomitant antiviral therapy and im-
munosuppressive therapy, which is absolutely required 881 Renal Transplantation and HCV Treatment           Du L et al.
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Diagram. Flow Diagram for Patient Work-Up
after renal transplantation.
Transplanted kidneys usually maintain their function 
with continuous administration of immunosuppres-
sants. Commonly used immunosuppressive regimens 
include   the tacrolimus (  FK506) regimen (FK506 +   myco-
phenolate mofetil [MMF] + prednisone) and the cyclospo-
rine A (CsA) regimen (CsA + MMF + prednisone) (3). These 
regimens often lead to massive viral replication, thereby 
accelerating the process of liver ﬁbrosis and decreasing 
the eﬃcacy of interferon (IFN) treatment (4, 5). High HCV 
load is also linked to other complications such as thyroid 
dysfunction, diabetes,  essential mixed cryoglobulinemia 
(EMC), and idiopathic thrombocytopenia. HCV-associat-
ed glomerulonephritis is an example of a direct impact 
to transplanted kidneys caused by viremia. In addition 
to the kidneys, other organs such as the liver are also se-
verely aﬀected by these combined complications of HCV 
infection (6). In several long-term clinical follow-up tri-
als, patient mortality following renal transplantation 
varied from 8% to 28% due to liver failure; the incidence 
rate of mortality is 3 times greater in HCV infected organ 
recipients (7, 8). A follow-up on patient survival rates 
with and without HCV infection is shown in Figure. Pa-
tients positive for HCV demonstrate a lower survival rate 
(9, 10). In theory, antiviral therapy should be used to treat 
HCV; however, the immunomodulatory IFN component 
in antiviral treatments increase donor-speciﬁc alloanti-
bodies and cause humoral rejection of the graft (11). IFN 
also leads to additional side eﬀects on hematopoietic 
cells. Therefore, the use of antiviral therapy in these HCV 
patients requires great caution to avoid the potentially 
fatal and complex pharmacological eﬀects on the trans-
planted kidneys or other organs (6).
2. Evidence Acquisition
Pubmed (NLM), LISTA (EBSCO), Web of Science (TS) were 
searched with key words "Renal Transplantation”, “Hepa-
titis C Virus”, “Antiviral Agents”, and “Immunosuppres-
sion” in recent 10 years, mostly recent 5 years. We also 
tried to obtain full articles and abstracts on the reference 
lists from retrieved documents. As the information 
about this topic was rare, small clinical trials and case 
reports were also included. The complexity of antiviral 
therapy, the management of patients on waiting list, the 
indications and regimens about treatment were studied.
3. Results
We found more than 40 papers including 7 small 
clinical trials about this topic. From the information we 
drew out following aspects.
3.1. Evaluation and Management of Patients on the Re-
nal Transplantation Waiting List
The treatment of HCV infection demands immune en-
hancement while kidney anti-rejection therapy requires 
immune suppression. An international consensus has 
been reached to conduct HCV testing on patients await-
ing renal transplantation (12). A similar system in Iran 
stratiﬁes patients for eligibility: all candidates are tested 
for an HCV marker and alanine aminotransferase (ALT), 
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and only the candidates whose results for both are nor-
mal qualify for the waiting list. Others are tested for HCV 
RNA; a patient with negative results qualiﬁes, while a 
patient with positive results requires liver biopsy. If the 
liver biopsy indicates chronic hepatitis, antiviral therapy 
will be administrated until the patient shows sustained 
virological response (SVR), at which point the patient can 
be added to the list. If diagnosed with compensated cir-
rhosis, the patient will be considered for kidney and liver 
co-transplantation, a procedure for which it is extremely 
diﬃcult to identify a donor. A liver biopsy indicating de-
compensated cirrhosis contraindicates transplantation 
(13, 14). The decision ﬂow is shown in Diagram, in which 
the result of the liver biopsy result is the key factor in de-
ciding whether a patient qualiﬁes for transplantation. As 
a gold standard to determine liver conditions, a liver bi-
opsy can detect or exclude complications such as occult 
cirrhosis. Moreover, it can guide the treatment plan for 
patients infected with HCV genotypes 1 or 4, which re-
quire a higher dosage and a longer course (15).
One third of ESRD patients with HCV infection can 
achieve SVR via IFN administration, and thus, antiviral 
therapy is recommended for those patients. The combi-
nation of IFN with ri  bavirin (RBV) has further improved 
the rate of SVR. After treatment, patients who have at-
tained SVR usually exhibit a long-term and durable virol-
ogy, biochemistry, and histology response (16). Several 
small clinical trials on dr    ug administration in ESRD pa-
tients were analyzed by Perico et al. (17). When 3 million 
units (MU) of common IFN was used weekly and 200 mg 
RBV was used 3 times per week for more than 24 weeks, 
more than 50% of patients achieved SVR—and the rate 
improved with lengthened treatment periods. The use of 
pegylated IFN further improved the SVR rate. The addi-
tion of RBV to the regimen may result in improved SVR, 
but with a greater risk of anemia (18-20). More details of 
these clinical trial ﬁndings are shown in Table 1.
Although eﬀective screening and treatment strategies 
have been implemented to help avoid dysfunction of the 
transplanted kidney, a big challenge in recrudescence 
and reinfection with HCV exists due to the side eﬀects 
of IFN and RBV, which lead to the inability for most ESDR 
patients to accomplish the entire standard therapy regi-
men identiﬁed as “888.” Patients also risk HCV infection 
from protracted blood exposure to externalities during 
renal transplantation surgery.
3.2. Indication that Treatment Is Necessary After Renal 
Transplantation
The questions of whether an antiviral treatment can 
be initiated and how to implement remain controver-
sial. In 2009, the guidelines regarding the diagnosis and 
treatment of hepatitis C, which were jointly amended by 
the American Association for the Study of Liver Diseases 
(AASLD), Infectious Diseases Society of America (IDSA), 
and American Society of Gastroenterology (ASG), de-
clared that antiviral therapy based on IFN is not recom-
mended for use in patients after renal transplantation 
due to the risk of acute rejection. This statement applies 
to patients with chronic kidney disease or to patients 
following organ transplantation. However, for patients 
with ﬁbrosing cholestatic hepatitis, IFN is necessary for 
slowing liver cirrhosis and extending long-term survival 
(21-23). Prior to this recommendation, Kidney Disease Im-
proving Global Outcome (KDIGO) published a guideline 
in 2008 that suggests the use of antiviral therapy after 
renal transplantation if patients have advanced liver dis-
ease such as liver ﬁbrosis; antiviral therapy is important 
to prevent liver-related death. The 2008 guideline also 
mentioned the necessity of this therapy for patients with 
ﬁbrosing cholestatic hepatitis (12, 21). Moreover, some be-
lieve that treatment recipients with HCV-related glomer-
ulonephritis should receive antiviral therapy actively; 
otherwise, the treatment will lead to deteriorating renal 
function or loss of the allograft (24).
To summarize these studies and guidelines, several ma-
jor points regarding when to initiate antiviral therapy in 
renal transplant recipients infected with HCV are listed 
below:
1) Renal transplantation recipients with stable renal 
and liver function require strict observation rather than 
antiviral therapy. Liver and renal function tests should 
be conducted every 3 months and the viral load should 
be evaluated every 6 months. In particular, a liver biopsy 
should be repeated every 3 years (25).
2) Patients exhibiting ﬁbrosing cholestatic hepatitis, 
advanced liver ﬁbrosis, or HCV-associated glomerulone-
phritis should initiate antiviral therapy because it has 
known eﬀects on long-term survival rates of both pa-
tients and allografts. Sustained suppression of necroin-
ﬂammation may result in regression of cirrhosis which, 
in return, leads to decreased morbidity.
3) If antiviral therapy is deemed necessary, clinicians 
should assess ﬁrst the risks and beneﬁts and then inform 
the patients. Treatment initiation can   only occur with 
both patient agreement and determination that the ben-
eﬁts outweigh the risks.
4) Because liver and renal function, the state of im-
munosuppression, and the maintenance regimen diﬀer 
from patient to patient, as do the HCV complications 
and the impact of antiviral drug side eﬀects, treatments 
should be individualized. All of these components re-
quire close evaluation before ﬁnal decisions regarding 
antiviral treatment can be made.
In addition, the risk for acute rejection is higher dur-
ing the ﬁrst year after transplantation surgery (11). Thus, 
it is strongly recommended to wait at least 1 year after 
the surgery to initiate antiviral therapy. Another study 
showed that antiviral treatment may yield a more eﬀec-
tive response if stable renal function and no acute rejec-
tion occur during the ﬁrst year after transplantation (26). 
The management on this stage is also shown in Diagram.883 Renal Transplantation and HCV Treatment           Du L et al.
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3.3. Treatment of Chronic HCV Infection
3.3.1. Standard Regimen
The 2009 edition of the diagnostic and treatment 
guidelines (AASLD/IDSA/ASG) for hepatitis C suggest that 
the standard treatment should be a combination of pe-
gylated IFN α (PEG-IFN α) and RBV. The speciﬁc dosage 
and duration diﬀer according to viral genotypes and pa-
tient response. Patients infected with HCV genotype 1 or 
4 should expect a 48-week treatment duration consisting 
of 180 μg PEG-IFN α-2a per week, administered by hypo-
dermic injection, and a daily weight-dependent dose of 
RBV, i.e. 1000 mg (body weight ≤ 75 kg) or 1200 mg (body 
weight > 75 kg). If PEG-IFN α-2b is used, a subcutaneous 
dose of 1.5 μg/kg should be administered weekly in addi-
tion to daily weight-dependent RBV, i.e. 800 mg (weight 
< 65 kg), 1000 mg (weight 65~85 kg), 1200 mg (weight 
85~105 kg), or 1400 mg (weight > 105 kg). Patients infected 
with HCV genotype 2 or 3 should expect a basic course of 
24 weeks with 800 mg RBV daily. If a patient cannot tol-
erate the side eﬀects, 3 MU of IFN can be used 3 times per 
week. In addition, the dose of PEG-IFN α-2a can be reduced 
to 135 μg per week and PEG-IFN α-2b to 1μg/kg per week. 
Combined RBV is still acceptable when reduction and side 
eﬀects such as anemia are closely monitored (22).
3.3.2. Reformed Regimen
What we had identiﬁed as stable renal function after 
transplantation was in fact not actually intact; non-im-
paired renal function includes either intact renal func-
tion or mild to moderate impairment due to HCV-related 
hemolysis, EMC, or other complications that are not in 
advanced stages (27, 28). Thus, the targets can be divided 
into 2 groups on the basis of renal function. Treatment 
with IFN alone is recommended for impaired renal func-
tion; it suppresses viral replication as well as imparts 
substantial therapeutic eﬀects on cryoglobulin-associat-
ed mesangial proliferative glomerulonephritis. Thus, IFN 
alone can reduce kidney damage and improve the condi-
tion of microscopic hematuria and hypertension. The 
recommended dosage is IFN at 3 MU 3 t  imes per week, 
PEG-IFN α-2a at   180 μg per week, or PEG-IFN α-2b at 1 μg/
kg per week (17). Since RBV mainly plays an immunosup-
pressive role in vivo, it was alone tested as a treatment 
to determine if it has any antiviral therapeutic value for 
reducing acute rejection. However, the risks associated 
with RBV alone far exceed any potential beneﬁts for treat-
ing impaired renal function. RBV is processed mainly by 
the kidneys. Consequently, RBV, alone or in combination 
with another therapy, is not recommended for patients 
with impaired renal function (5).
Combined treatment is applicable for patients with 
complete renal function. According to actual patient 
glomerular ﬁltration rates (GFR), RBV is used to supple-
ment the recommended IFN dose. The ultimate goal is to 
achieve a blood concentration of 10–15 μmol/L over t    he 
long term. A trial was conducted previously that used 
a low-dose combination therapy consisting of the com-
mon 1 MU of IFN 3  times per week plus 600 mg of RBV per 
day (29). The regimens described above and their extrap-
olated SVR rates are shown in Table 2 (30-33). In summary, 
the decision to initiate antiviral therapy depends on liver 
function; if liver function deterioration can potentially 
lead to loss of renal function, treatment should be ini-
tiated immediately. The renal function of each patient 
dictates the choice of regimen; therefore, the regimen 
should be individualized and patients should be closely 
monitored.
3.4. Adjusted Immunosuppressive Regimen for HCV Pa-
tients After Renal Transplantation
Before initiating antiviral therapy, the immunosup-
pression regimen should be adjusted accordingly. When 
a patient is conﬁrmed with HCV infection, it is reason-
able to reduce the dosage of immunosuppressants to the 
lowest dose at which an immunosuppressive state can 
be maintained and liver damage is minimized. MMF me-
tabolites can inhibit HCV replication eﬀectively; thus, an 
improved long-term survival rate is achieved in patients 
without administering antiviral treatment. Further stud-
ies are needed to demonstrate how MMF metabolites are 
processed and removed when used alongside antiviral 
therapy. All current immunosuppressive regimens in-
clude MMF (34). In animal experiments, CsA was able to 
inhibit HCV replication, independent of its immuno-
suppressive activity. This ﬁnding was corroborated by 
a retrospective cohort study in Germany, which dem-
onstrated that the renal grafts in patients receiving CsA 
function better than in patients receiving FK506, but no 
signiﬁcant diﬀerences were observed in viral replication 
and development of liver ﬁbrosis (35). Therefore, the CsA 
regimen may have better overall eﬃcacy in HCV patients 
when initiated after renal transplantation (36); however, 
an analysis on cost-eﬀectiveness showed that the FK506 
regimen is far more advantageous than the CsA regimen. 
Notably, this statement is currently a topic of consider-
able debate in the ﬁeld due to the lack of prospective 
clinical studies.
4. Conclusions 
Because of the speciﬁcity of patients and disease state, 
no consensus has been reached on the eﬀect of modiﬁed 
antiviral therapy on renal transplantation patients, and 
large clinical trials to obtain statistically sound conclu-
sions are diﬃcult to conduct due to the unique nature 
of this disease. Nonetheless, several small trials have re-
ported satisfactory curative eﬀects, i.e. the SVR reached 
62% with no harm to renal function (37). Overall, the opti-
mal regimen for HCV patients after renal transplantation 
remains out of reach. We need safer and more eﬀective 
drugs or alternative therapies. The present advent of di-
rect-acting antiviral (DAA) therapies are the biggest ad-
vance. These drugs speciﬁcally target the HCV-encoded 
nonstructural 3/4A (NS3/4A) serine protease and NS5B 
RNA-dependent RNA polymerase (RdRp) (38, 39). The ser-884 Renal Transplantation and HCV Treatment Du L et al.
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ine protease NS3/4A is used by HCV for posttranslational 
processing and viral replication; it is the ﬁrst successful 
target of DDAs. Protease inhibitors have been demon-
strated to be potent inhibitors of viral replication. The 
ﬁrst 2 DAAs are the linear serine protease inhibitors, tela-
previr (TVR) and boceprevir (BOC) (40). They both have 
ﬁnished phase III trials and will be available within the 
next year. However, resistance quickly develops when 
this type of compound is used alone (41). Hence, the ad-
dition of this class of compound to the mainstream drug 
arena is a current developing paradigm.
Two phase II, multicenter studies of TVR combined with 
PEG-IFN α-2a and RBV in untreated patients infected with 
HCV genotype 1 resulted in the addition of TVR and sig-
niﬁcantly increased rates of SVR, albeit with enhanced 
discontinuation due to adverse events (42, 43). Ra  sh and 
pruritus were the major adverse events in the groups 
that received TVR. They could be monitored during the 
treatment period. Both top ical antiallergenic agents and 
topical and systemic antipruritic agents were used; how-
ever, severe rash necessitated corticosteroid treatment. 
Since immunosuppressive regimens already include 
prednisone, the rate of adverse events might be lower in 
patients after transplantation. In another randomized, 
stratiﬁed, partially placebo-controlled, partially double-
blind, phase II study, we conducted a group study without 
RBV, i.e. TVR and PEG-IFN α-2a only for 24 weeks. However, 
a better SVR rate than the control group (which received 
the standard regimen) was achieved (44). A regimen with-
out RBV is possible; patients who cannot tolerate the side 
eﬀects of RBV will beneﬁt greatly from this regimen, espe-
cially the transplantation patients. BOC can also elevate 
the SVR rate in similar clinical trials (45), but anemia is 
a class eﬀect of linear protease inhibitors, and it is more 
common with BOC compared to TVR (40). Thus, the use 
of TVR might make women more suitable to frozen trans-
plantation and both protease inhibitors call for a stable 
renal function and tolerance.
However, the actual eﬀects of upcoming protease inhibi-
tors will be examined in a special group of patients. High-
ly anticipated RNA interference therapies still remain in 
the research and development stage (46). Given the high 
cost of current HCV regimens and numerous side eﬀects, 
HCV-infected recipients have to face a double burden, 
i.e. ﬁnancially and physically. Careful decision-making is 
needed before the initiation of such treatment and it of-
ten calls for a ﬁne balance between risk and beneﬁt.
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